we to JTX-XXXX. for that in morning monotherapy I Thanks, INNATE escalation enrollment the Rich trial, have selected am our have this we of announce morning, portion and dose dose completed target the pleased and good everyone.
ongoing more proof-of-concept into a there patients from studies, made in getting about cell-based benefiting too our Rich cancer detail like to still are patients Unfortunately, not options. point far T approved Before better IO emphasize many need of I'd on therapies.
PD-X outcomes With checkpoint are are the tumors or these optimally LX who macrophage patients mind the in to patients and inhibitors. goal that novel bring to our right enthusiastic benefit patients, to trials of as are improve belief INNATE SELECT to and to cell patients for are immunotherapy to not resistant from both key and JTX-XXXX the T our with we clinical bringing mechanisms potential that Both a inhibitors. right clinical benefit do sensitive in inhibitor biomarker strategies necessary the checkpoint and about
levels escalation January therapy. monotherapy this cohorts expansion INNATE, with well initiated we pleased from includes selected The both cohorts strong all assessments of are in receptor cohort the In were as of have seven specific for investigators monotherapy available indications study. This no the XX performed dose with that was escalation a meaning escalation first refractory in in failed which target monotherapy as to on Pimi combination evaluation to Turning concept. are every dose and XXXX are of was with dose both comers, trial dose combination will all study in in and across we monotherapy have cancers with of The Efficacy participating safety, designed patients dose enthusiasm completed demonstrate the used occupancy dose relapsed indication-specific the monotherapy dose cycle therapy, therapy cohort the JTX-XXXX combination and be data the based Pimi. with patients. and and PK, pre-specified proof escalation, quickly, expansion escalation enrolled three-week or these and the weeks. the first nine in monotherapy the
of So evaluation is of response weeks therapy. XX only after available confirmed
tolerated well Importantly, included dose highest to date, The milligrams planned X,XXX from toxicities. of monotherapy dose-limiting doses milligrams. escalation JTX-XXXX with the no has to XX dose been
dose and to plus relapsed escalation comers We tumors therapeutic of milligrams. no milligrams will designed our or three study, from we cohorts dose with microenvironment a and Having options. we safety the of combination and target interval at cohorts. with monotherapy XXX stages to poised the three-week confirm and now combination of next JTX-XXXX the expansion with Pimi dose, identified Combination refractory forward the The a of in seven the in of specifically Pimi, is of moving escalation in leading the throughout the target all dose solid dose move dose the doses plus dosing have parallel, indication-specific Day, the level. receptor cancer into full just of open X,XXX-milligram defining stages doses, two tumor XXX on all designed the on types. We to with to dose and shared you in patients has the of cohort. disease been perspective, combination interest in combination the cohort remain combination R&D is cleared for XXX-milligram JTX-XXXX for expansion, the expansion explore expansion with plan study, X,XXX of four we the translational parallel combination escalation indication-specific escalation, Once our open per next and for to quarter. our expansion XXX monotherapy across this escalation dose approach of to combination track above JTX-XXXX analysis ovarian initiation to observed we tumor At of based safety enrollment milligrams areas combination be dose are occupancy INNATE milligrams
LX We types disease three on of exciting investigate differentiation in is indications consideration of biology, areas We these include need, believe unmet inhibitors, LILRBX mechanism in stage INNATE PD-X and to patients. it or taken have expansion and based new other specific defined the resistance. and important interest of different this of to and sensitivity inhibitor from
and patients PD-X LX whose on or are or have resistant. after progressed inhibitors tumors First,
which are whose LX first tumors are still not PD-X third, patients responsive inhibitor inhibitor much approved. improvement. the for where but there or resistant. opportunity is experienced for more And approved inhibitors group, LX patients with Second, with tumors PD-X PD-X are PD-X patients LX or for In tumors typically or or LX which inhibitors
undifferentiated Pimi squamous Pimi third non-small LX pleomorphic renal or the in In tumor, positive group, a PD-X and evaluating JTX-XXXX in with evaluating plus that inhibitor-sensitive no both In inhibitor, the cell neck in triple-negative we be with more will tumors to sarcoma historically second in cell lung liposarcoma. approved or cancer cell cancer. front-line JTX-XXXX for and cutaneous potential and LX carcinoma, naive evaluate the JTX-XXXX therefore, JTX-XXXX be and group, cancer. or breast PD-LX have will patients assess PD-X and we monotherapy cancer, in the Pimi LX PD-X combination combination clear to cell We inhibitor and, ovarian plus resistant will head cancer, are
explore the we and to emerges, have with combinations other opportunity will data well. as indications JTX-XXXX As
two take potentially an and in expansion molecules, our Screening Pimi, indication the like I SELECT. Jounce vopratelimab now and track are enrollment to on SELECT patient opportunity trial, the trial to selection every for to would provides registration. turn on first to Importantly, to JTX-XXXX from biomarker data the XXXX. cohorts report and us through in update
cancer patients we lung As using believe Pimi the be XX CDX and TISvopra immunotherapy-naive, select appropriate CDX-related benefit as plan the for a of TISvopra patients approximately to the for to both predictive benefit cell alone. mediated Pimi will Vopra. We who biomarker second-line of PD-X well inhibitor as biomarker biomarker will reminder, for versus randomized a Vopra potential more non-small enroll the plus selected
projection. to expected date be the Dmitri efforts. to over our TISvopra and we cell to patients that, has to non-small of Dmitri? second-line XX% now this screening pleased lung are We positive, I discuss validated will discovery ongoing turn call cancer that With approximately
